DexCom price target raised to $160 from $151 at Raymond James

Raymond James raised the firm’s price target on DexCom to $160 from $151 and keeps a Strong Buy rating on the shares. Raymond James was hoping for a bit more upside, but DexCom added a record number of new users in Q1, which is the leading indicator of future revenue growth, and lifted the low end of its revenue guidance, the analyst tells investors in a research note.